News
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel ...
The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...
18hon MSN
There's a clear downside to the Norwegian policy that encourages allowing elderly people to live at home for as long as ...
FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.
The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.
While mom was alive, we thanked God for the time she spent with us. Her life was much more interesting and fascinating than I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results